Lyra Therapeutics (LYRA) Accounts Payables (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Accounts Payables of $663000.0 in Q4 2025, up 5.74% on a QoQ basis from $627000.0 in Q3 2025, and down 43.77% YoY from $1.2 million in Q4 2024.
Lyra Therapeutics (LYRA) Accounts Payables (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Accounts Payables for 7 consecutive years, with $663000.0 the latest figure, recorded in Q4 2025.
- Accounts Payables for Q4 2025 came in at $663000.0, down 43.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $663000.0 (down 43.77% YoY), and the FY2025 annual result was $663000.0, down 43.77% from the prior year.
- Accounts Payables for Q4 2025 stood at $663000.0, up from $627000.0 in the prior quarter.
- The five-year high for Accounts Payables was $5.1 million in Q3 2023, with the low at $627000.0 in Q3 2025.
- A 5-year average of $2.5 million and a median of $2.5 million in 2022 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables jumped 449.43% in 2021 and sank 86.32% in 2025, its largest moves.
- Lyra Therapeutics' Accounts Payables stood at $3.1 million in 2021, then retreated by 16.29% to $2.6 million in 2022, then climbed by 19.69% to $3.1 million in 2023, then sank by 62.34% to $1.2 million in 2024, then tumbled by 43.77% to $663000.0 in 2025.
- The last three Accounts Payables figures came in at $663000.0 (Q4 2025), $627000.0 (Q3 2025), and $680000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 663,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 627,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 725,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 4.19 Mn |
| Mar 31, 2023 | 3.95 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 2.91 Mn |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 1.17 Mn |